Phys · oncological
Breakthrough Cancer Pain AND Opioid Titration
Also known as Breakthrough Cancer Pain AND Opioid Titration · breakthrough cancer pain and opioid titration
Consultant-physician depth guide to Breakthrough Cancer Pain AND Opioid Titration for FRACP DWE/DCE preparation — presentation, differentials, investigations, management, complications and exam angles.
On this page
Study tools
Your progress
Saved on this device.
Practise this topic
Target exams
Red flags
- Missed urgency or delayed escalation in Breakthrough Cancer Pain AND Opioid Titration turns a salvageable presentation into preventable harm
- Treating the label without confirming the mechanism leads to wrong therapy in Breakthrough Cancer Pain AND Opioid Titration
- Ignoring multimorbidity and drug interactions while managing Breakthrough Cancer Pain AND Opioid Titration is a classic exam and clinical trap
- Failing to document the shared plan and safety-net advice after Breakthrough Cancer Pain AND Opioid Titration loses follow-through
- Using recalled thresholds without a cited source is forbidden — verify before acting
The answer first
Breakthrough cancer pain (BTcP) is a transient exacerbation of pain that occurs against a background of otherwise stable persistent pain controlled by around-the-clock analgesia. The FRACP candidate must defend three thresholds: the 5-10 minute onset that defines the rapid onset requirement for rescue opioids, the 30-60 minute duration that distinguishes BTcP from poorly controlled background pain, and the 10-20 per cent of the total daily opioid dose as the starting rescue dose. The first-line rescue agent for BTcP is a rapid-onset opioid (transmucosal fentanyl) when the patient is opioid-tolerant; otherwise, an immediate-release opioid at 10-20 per cent of the total daily dose is used. [1] [3]
The answer-first synthesis is: confirm the diagnosis (transient exacerbation against a stable background), classify the subtype (spontaneous/idiopathic, incidental/predictable, or end-of-dose failure), titrate the rescue opioid, address precipitants, and integrate non-pharmacological options (radiotherapy, nerve blocks, palliative care). [1] [9]
References9ShowHide
- [1]Mestdagh F, Steyaert A, Lavand'homme P Cancer Pain Management: A Narrative Review of Current Concepts, Strategies, and Techniques Current oncology (Toronto, Ont.), 2023.PMID 37504360
- [2]Abdel Shaheed C, Hayes C, Maher CG et al. Opioid analgesics for nociceptive cancer pain: A comprehensive review CA: a cancer journal for clinicians, 2024.PMID 38108561
- [3]Dalal S, Bruera E Pain Management for Patients With Advanced Cancer in the Opioid Epidemic Era American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2019.PMID 31099619
- [4]Wiffen PJ, Wee B, Derry S et al. Opioids for cancer pain - an overview of Cochrane reviews The Cochrane database of systematic reviews, 2017.PMID 28683172
- [5]Prommer EE Pharmacological Management of Cancer-Related Pain Cancer control : journal of the Moffitt Cancer Center, 2015.PMID 26678968
- [6]Bhaskar A Interventional pain management in patients with cancer-related pain Postgraduate medicine, 2020.PMID 32799614
- [7]Virgen CG, Kelkar N, Tran A et al. Pharmacological management of cancer pain: Novel therapeutics Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022.PMID 36272265
- [8]Pautex S, Vogt-Ferrier N, Zulian GB Breakthrough pain in elderly patients with cancer: treatment options Drugs & aging, 2014.PMID 24817569
- [9]Virizuela JA, Escobar Y, Cassinello J et al. Treatment of cancer pain: Spanish Society of Medical Oncology (SEOM) recommendations for clinical practice Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2012.PMID 22721793